Screening of selective histone deacetylase inhibitors by proteochemometric modeling
暂无分享,去创建一个
Jun Gao | Qi Liu | Qingchen Zhang | Dingfeng Wu | Ruixin Zhu | Qi Huang | Zhi-Wei Cao | Yida Zhang
[1] Peteris Prusis,et al. Proteochemometric modeling of HIV protease susceptibility , 2008, BMC Bioinformatics.
[2] Eric Verdin,et al. Histone deacetylase HDAC8 associates with smooth muscle α‐actin and is essential for smooth muscle cell contractility , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] P. Bertrand. Inside HDAC with HDAC inhibitors. , 2010, European journal of medicinal chemistry.
[4] H. Rikiishi,et al. Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells , 2011, Journal of biomedicine & biotechnology.
[5] Takayoshi Suzuki,et al. Explorative study on isoform-selective histone deacetylase inhibitors. , 2009, Chemical & pharmaceutical bulletin.
[6] Shandar Ahmad,et al. Proteochemometric Recognition of Stable Kinase Inhibition Complexes Using Topological Autocorrelation and Support Vector Machines , 2010, J. Chem. Inf. Model..
[7] Peteris Prusis,et al. QSAR and proteo-chemometric analysis of the interaction of a series of organic compounds with melanocortin receptor subtypes. , 2003, Journal of medicinal chemistry.
[8] H. Hamm,et al. G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. , 2005, The Journal of biological chemistry.
[9] Wen‐Ming Yang,et al. Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation* , 2000, The Journal of Biological Chemistry.
[10] N. Bertos,et al. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. , 2002, Nucleic acids research.
[11] Eric Verdin,et al. Histone Deacetylase 7 Functions as a Key Regulator of Genes Involved in both Positive and Negative Selection of Thymocytes , 2007, Molecular and Cellular Biology.
[12] Oliver Distler,et al. Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? , 2011, Expert review of clinical immunology.
[13] Peteris Prusis,et al. Improved approach for proteochemometrics modeling: application to organic compound - amine G protein-coupled receptor interactions , 2005, Bioinform..
[14] David A. Gough,et al. Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..
[15] I. Longden,et al. EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.
[16] Xi Chen,et al. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study , 2011, BMC Bioinformatics.
[17] Thomas Gärtner,et al. Ligand Prediction from Protein Sequence and Small Molecule Information Using Support Vector Machines and Fingerprint Descriptors , 2009, J. Chem. Inf. Model..
[18] Ruixin Zhu,et al. Investigations on Inhibitors of Hedgehog Signal Pathway: A Quantitative Structure-Activity Relationship Study , 2011, International journal of molecular sciences.
[19] Qi Liu,et al. Virtual Drug Screen Schema Based on Multiview Similarity Integration and Ranking Aggregation , 2012, J. Chem. Inf. Model..
[20] Ruixin Zhu,et al. Multi-target QSAR Study in the Analysis and Design of HIV-1 Inhibitors† , 2010 .
[21] Abhik Seal,et al. Docking study of HIV-1 reverse transcriptase with phytochemicals , 2011, Bioinformation.
[22] Jarl E. S. Wikberg,et al. Proteochemometric Modeling of Drug Resistance over the Mutational Space for Multiple HIV Protease Variants and Multiple Protease Inhibitors , 2009, J. Chem. Inf. Model..
[23] P. Labute. A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.
[24] Joel R. Bock,et al. A New Method to Estimate Ligand-Receptor Energetics* , 2002, Molecular & Cellular Proteomics.
[25] George Karypis,et al. Multi-Assay-Based Structure-Activity Relationship Models: Improving Structure-Activity Relationship Models by Incorporating Activity Information from Related Targets , 2009, J. Chem. Inf. Model..
[26] Yong Eun Kim,et al. A Structure‐Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc‐Chelating Groups , 2010, ChemMedChem.
[27] Zhen Lu,et al. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer , 2007, International journal of cancer.
[28] Jun Gao,et al. A new protein-ligand binding sites prediction method based on the integration of protein sequence conservation information , 2011, BMC Bioinformatics.
[29] James Bradner,et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.
[30] P. Prusis,et al. Proteochemometric modelling of antibody-antigen interactions using SPOT synthesised peptide arrays. , 2007, Protein engineering, design & selection : PEDS.
[31] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[32] L. Buydens,et al. Facilitating the application of Support Vector Regression by using a universal Pearson VII function based kernel , 2006 .
[33] Peteris Prusis,et al. Proteochemometric Mapping of the Interaction of Organic Compounds with Melanocortin Receptor Subtypes , 2005, Molecular Pharmacology.
[34] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[35] Yoshiharu Kawaguchi,et al. MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation , 2002, The EMBO journal.
[36] Andries Petrus Engelbrecht,et al. Using OVA modeling to improve classification performance for large datasets , 2012, Expert Syst. Appl..
[37] K. Fidelis,et al. Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme‐Ligand Space. , 2009 .
[38] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[39] Jean-Philippe Vert,et al. Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.
[40] Jun Xu,et al. Drug-Like Index: A New Approach to Measure Drug-Like Compounds and Their Diversity. , 2001 .
[41] Heidi E. Hamm,et al. Gβγ Binds Histone Deacetylase 5 (HDAC5) and Inhibits Its Transcriptional Co-repression Activity* , 2005, Journal of Biological Chemistry.
[42] Zhiwei Cao,et al. Insight into potential toxicity mechanisms of melamine: an in silico study. , 2011, Toxicology.
[43] Qi Kang,et al. Comparison of Ligand-, Target Structure-, and Protein-Ligand Interaction Fingerprint-based Virtual Screening Methods , 2011 .
[44] Ruixin Zhu,et al. Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening , 2011, International journal of molecular sciences.
[45] Laurent Schaeffer,et al. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression , 2005, Nature Neuroscience.
[46] Constance L. Cepko,et al. HDAC4 Regulates Neuronal Survival in Normal and Diseased Retinas , 2009, Science.
[47] M. Salto‐Tellez,et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.